Invacare Corp. has added Barbara W. Bodem to its board of directors, effective Aug. 18.
In a news announcement, Invacare said Bodem is senior VP at Mallinckrodt Pharmaceuticals, based in St. Louis.
“With more than 20 years of corporate finance experience at leading pharmaceutical and medical device companies, Ms. Bodem offers strong finance, senior management and industry expertise,” the announcement said.
Invacare Chairman/CEO/President Matthew E. Monaghan said of the appointment, “We are excited to welcome Barbara to the Invacare board of directors. Barbara is an accomplished business leader with outstanding experience at global pharmaceutical and medical device companies, which will enable her to provide insight and counsel to our company and fellow board members. I am pleased to be growing our board with strong leaders who bring deep medical, commercial and business experience to guide us for the future. Barbara will be a great addition to our already strong board.”
On Aug. 18, Invacare declared quarterly cash dividends of $.0125 on common shares and $.011364 on Class B common shares, payable to shareholders on Oct. 16.
In late July, Invacare announced it had exited the injunctive phase of the U.S. Food & Drug Administration (FDA) consent decree that had restricted some of the manufacturer’s product development and sales activities since December 2012. The FDA announcement cleared Invacare to design and manufacture wheelchairs at its Taylor Street facility in Elyria, Ohio.
Invacare announced the global launch of its TDX SP2 power wheelchair with LiNX Technology, plus Motion Concepts’ Ultra Low Maxx Positioning System, earlier this month.
